Ivermectin and COVID-19 - many studies

---

Why It's Important Everyone Should Have Ivermectin Handy - Nov 2024

Substack includes:

• "The med has won a Nobel Prize for its safety and efficacy."
• US: 1 year of Ivermectin - zero deaths, 1 year of Tylenol 164 deaths
• Ivermectin will be protective for 3.5 days.
• "Early Treatment (if infected with anything, bacterial, viral, whatever) - 0.4 mg/kg daily. Continue use up to a few days after symptoms subside. Symptoms might subside in just a few hours."

---

4-year history of (political) suppression of Ivermectin's ability to fight COVID (which continues) - Sept 2024

TrialSiteNews
which references
Guest Editorial Negative Evidence: Repurposed Drugs for COVID-19: the Partisan Bone of Contention. Part II
Journal of American Physicians and Surgeons Volume 29 Number 3 Fall 2024

 Download the PDF from VitaminDWiki

66 REFERENCES

1. Orient J. Negative evidence: repurposed drugs for COVID-19: the partisan bone of contention. Part I. J Am PhysSurg 2024;29(2):34-46.
2. Orient J. Negative evidence: antibody-dependent enhancement. J Am Phys Surg 2022;27(1):2-6.
3. Orient JM. Negative evidence: COVID-19 vaccines and cancer. J Am Phys Surg 2023;28(1):2-10.
4. Orient JM. Negative evidence: COVID-19 vaccines and fertility. J Am Phys Surg 2022;27(3):69-77.
5. Orient JM. Negative evidence: COVID-19 vaccines and neurological disorders. J Am Phys Surg 2023;28(3):74-80.
6. Orient JM. Negative evidence: COVID-19 vaccines and sudden deaths. J Am Phys Surg 2023;28(2):38-47.
7. Orient JM. Negative evidence: COVID-19 vaccines and disorders of hemostasis. J Am Phys Surg 2022;27(4):98-107.
8. Orient JM. Negative evidence: postmortem examinations of post-COVID-19 vaccine fatalities. J Am Phys Surg 2022;27(2):35-41.
9. Orient JM. Beyond negative evidence: lessons from the disputes on DNA contamination of COVID-19 vaccines. J Am Phys Surg 2023;28(4):106-112.
10. Orient JM. Negative evidence: the Gordian knot of the dispute on the origin of SARS-CoV-2. J Am Phys Surg 2024;29(1):2-10.
11. Thompson WC, Scurich N. When does absence of evidence constitute evidence of absence? Forensic Sci Int 2018;291:e18-e19. doi: 10.1016/J. FORSCIINT.2018.08.040.
12. InfoHealer. Politicization, polarization & power asymmetry. Information Heals; Dec 3, 2022. Available at: https://neutralresearcher.substack.com/p/ politicization-polarization-and-power. Accessed Feb 2, 2023.
13. InfoHealer. Partisan silos, bubbles and echo chambers. Politicization, polarization & power asymmetry; Dec 3, 2022. Available at: https:// neutralresearcher.substack.com/i/88363170/partisan-silos-bubbles-and- echo-chambers. Accessed Feb 6, 2024.
14. Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. J Antibiot 2017;70(5):495-505. doi: 10.1038/ja.2017.11.
15. Omura S, Crump A. The life and times of ivermectin—a success story. Nat Rev Microbiol 2004;2(12):984-989. doi: 10.1038/nrmicro1048.
16. Low ZY, Yip AJW, Lal SK. Repositioning ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. Biochim Biophys Acta Mol Basis Dis 2022;1868(2). doi: 10.1016/J.BBADIS.2021.166294.
17. Awad H, Hassan B, Dweek S, et al. Repurposing potential of the antiparasitic agent ivermectin for the treatment and/or prophylaxis of COVID-19. Pharmaceuticals (Basel) 2022;15(9). doi: 10.3390/PH15091068.
18. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020;73(9):593-602. doi: 10.1038/S41429-020-0336-Z.
19. Zaidi AK, Dehgani-Mobaraki P. RETRACTED ARTICLE: The mechanisms of action of ivermectin against SARS-CoV-2: an evidence-based clinical review article. J Antibiot (Tokyo) 2022;75(2):122. doi: 10.1038/S41429-021-00430-5.
20. Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. J Antibiot (Tokyo) 2022;75(2):60- 71. doi: 10.1038/S41429-021-00491-6.
21. Buonfrate D, Chesini F, Martini D, et al. High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double­blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. Int J Antimicrob Agents 2022;59(2):106516. doi: 10.1016/J.IJANTIMICAG.2021.106516.
22. Viper K. How bad research clouded our understanding of Covid-19. Early studies of Covid-19 therapeutics turned out to be fabricated or suspicious. That's a huge problem for science. Vox; Dec 17, 2021. Available at: https://web.archive.org/web/20220114091211/https://www. vox.com/ future-perfect/22776428/ivermectin-science-publication-research-fraud. Accessed Aug 16, 2024.
23. Meyerowitz-Katz G. 'Science is flawed': COVID-19, ivermectin, and beyond. Medical News Today, Dec 11, 2021. Available at: https://www. medicalnewstoday.com/articles/science-is-flawed-covid-19-ivermectin- and-beyond#How. Accessed Aug 20, 2024.
24. NIH. Table 7b. Ivermectin: Selected Clinical Data. COVID-19 Treatment Guidelines; Mar 6, 2023. Available at: https://web.archive.org/web/20240212161241/https://www.covid19treatmentguidelines.nih.gov/ tables/ivermectin-data/. Accessed Aug 20, 2024.
25. Hazan S, Dave S, Gunaratne AW, et al. Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients. Future Microbiol 2022;17(5):339-350. doi: 10.2217/FMB-2022-0014.
26. The long awaited debate of Covid science: a team of experts rebut the expert opinions of BC's College of Physicians and Surgeons. Available at: https://pierrekorymedicalmusings.com/pXthe-long-awaited-debate-of- covid. Accessed Aug 16, 2024.
27. COVID-19 early treatment: real-time analysis of 4,623 studies. Available at: https://c19early.org/. Accessed Aug 15, 2024.
28. CDC Archives Home. Rapid increase in ivermectin prescriptions and reports of severe illness associated with use of products containing ivermectin to prevent or treat COVID-19. Available at: https://archive.cdc.gov/#/ details?url=https://emergency .cdc.gov/han/2021/han00449.asp. Accessed Aug 16, 2024.
29. Temple C, Hoang R, Hendrickson RG. Toxic effects from ivermectin use associated with prevention and treatment of Covid-19. N Engl J Med 2021;385(23):2197-2198. doi: 10.1056/NEJMC2114907.
30. Woo E. How Covid misinformation created a run on ivermectin. NY Times, Sep 28, 2021. Available at: https://web.archive.org/web/20240405163816/ https://www.nytimes.com/2021/09/28/technology/ivermectin-animal- medicine-shortage.html. Accessed Aug 16, 2024.
31. Lust EB, Barthold C, Malesker MA, Wichman TO. Human health hazards of veterinary medications: information for emergency departments. J Emerg Med 2011;40(2):198-207. doi: 10.1016/J.JEMERMED.2009.09.026.
32. Langford C. Fifth Circuit sides with ivermectin-prescribing doctors in their quarrel with the FDA. Courthouse News Service; Sep 1, 2023. Available at: https://www.courthousenews.com/fifth-circuit-sides-with-ivermectin- prescribing-doctors-in-their-quarrel-with-the-fda/. Accessed Aug 16, 2024.
33. Reuters Fact Check. Ivermectin still not FDA-approved to treat COVID. Reuters; Aug 30, 2023. Available at: https://www.reuters.com/article/ factcheck-fda-ivermectin-covid-idUSL1N3AB1PS/. Accessed Aug 16, 2024.
34. Bond P. FDA Settles lawsuit over ivermectin social media posts. Newsweek; Mar 22, 2024. Available at: https://www.newsweek.com/fda-settles-lawsuit- over-ivermectin-social-media-posts-1882562. Accessed Aug 16, 2024.
35. Cohen P, Gebo K. COVID-19: Management of adults with acute illness in the outpatient setting. UpToDate; Jul 29, 2024. Available at: https://www. uptodate.com/contents/covid-19-management-of-adults-with-acute- illness-in-the-outpatient-setting. Accessed Aug 16, 2024.
36. NIH. Ivermectin. COVID-19 Treatment Guidelines; Dec 20, 2023. Available at: https://web.archive.org/web/20240816214157/https://www. covid19treatmentguidelines.nih.gov/therapies/miscellaneous-drugs/ ivermectin/. Accessed Aug 16, 2024.
37. NIH. Archived. Final NIH Coronavirus Disease (COVID-19) Treatment Guidelines (Feb 29, 2024). Available at: https://web. archive.org/web/20240816204148/https://wayback.archive-it. org/4887/20240626155208/https://www.covid19treatmentguidelines.nih. gov/. Accessed Aug 16, 2024.
38. Reis G, Silva EASM, Silva DCM, et al. Effect of early treatment with ivermectin among patients with Covid-19. N Engl J Med 2022;386(18):1721-1731. doi: 10.1056/NEJMOA2115869.
39. Lim SCL, Hor CP, Tay KH, et al. Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial. JAMA Intern Med 2022;182(4):426-435. doi: 10.1001/JAMAINTERNMED.2022.0189.
40. Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. N Engl J Med 2022;387(7):599- 610. doi: 10.1056/NEJMOA2201662.
41. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial. JAMA 2023;329(11):888-897. doi: 10.1001/JAMA.2023.1650.
42. Frost Radar report affirms healthcare providers can benefit from generative AI and CDSS innovation. Wolters Kluwer; Jan 24, 2024. Available at: https:// www.wolterskluwer.com/en/expert-insights/frost-radar-highlights-wk- outstanding-clinical-decision-support-system. Accessed Aug 16, 2024.
43. FDA. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19; Mar 5, 2021. Available at: https://web.archive.org/web/20210806053833/ https://www.fda.gov/consumers/consumer-updates/why-you-should-not- use-ivermectin-treat-or-prevent-covid-19. Accessed Aug 16, 2024.
44. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. Available at: https://web.archive.org/web/20210805102002/ https://www.who.int/news-room/feature-stories/detail/who-advises-that- ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Accessed Aug 16, 2024.
45. European Medicines Agency. EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials. News; Mar 22, 2021. Available at: https://web.archive.org/ web/202201 17073906/https://www.ema.europa.eu/en/news/ema- advises-against-use-ivermectin-prevention-treatment-covid-19-outside- randomised-clinical-trials. Accessed Aug 16, 2024.
46. Ragó Z, Tóth B, Szalenko-Tokés Á, et al. Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection. Geroscience 2023;45(4):2179. doi: 10.1007/S11357-023-00756-Y.
47. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther 2021;28(4):e434. doi: 10.1097/MJT.0000000000001402.
48. Kirsch S. ABIM: 'Follow the consensus, not the science. Saving lives is not a priority.' Steve Kirsch's Newsletter; Aug 14, 2024. Available at: https://kirschsubstack.com/p/abim-follow-the-consensus-not– #the?r=1sq8ef&utm_medium=ios&triedRedirect=true. Accessed Aug 15, 2024.
49. Lawrence JM, Meyerowitz-Katz G, Heathers JAJ, Brown NJL, Sheldrick KA. The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable. Nature Medicine 2021;27(11):1853-1854. doi: 10.1038/ s41591-021-01535-y.
50. Schraer, R, Goodman J. Ivermectin: How false science created a Covid "miracle” drug. BBC; Oct 6, 2021. Available at: https://www.bbc.com/news/ health-58170809. Accessed Aug 13, 2024.
51. Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evid Based Med 2022;27(3):156- 158. doi: 10.1136/BMJEBM-2021-111678.
52. Molento MB. Ivermectin against COVID-19: the unprecedented consequences in Latin America. One Health 2021 ;13. doi: 10.1016/J. ONEHLT.2021.100250.
53. Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Tropical Med Hygiene. 2020;102(6):1156-1157. doi: 10.4269/AJTMH.20-0271.
54. Davis JJ. Will ivermectin cure COVID-19? Op-Med; Feb 2, 2012. Available at: https://web.archive.org/web/20210525021615/https://opmed.doximity. com/articles/will-ivermectin-cure-covid-19. Accessed Aug 16, 2024.
55. Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta­analyses. In: Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series; Sep 22, 2008:243-296. doi: 10.1002/9780470712184. CH9.
56. InfoHealer. Not so unexpected stalemate. The partisan divide over COVID-19; Feb 4, 2023. Available at: https://neutralresearcher.substack. com/i/92334383/not-so-unexpected-stalemate. Accessed Feb 6, 2024.
57. Quote Investigator. Quote origin: insanity is doing the same thing over and over again and expecting different results. Available at: https:// quoteinvestigator.com/2017/03/23/same/. Accessed Aug 16, 2024.
58. InfoHealer. Politicized Rx: Negative impact of politicization on availability of safe, effective and affordable therapies. Information Heals; Aug 10, 2024. Available at: https://neutralresearcher.substack.com/p/politicized-rx. Accessed Aug 21, 2024.
59. Gill D. Who wants to repurpose cheap drugs? UCLA Anderson Review; Jul 23, 2023. https://anderson-review.ucla.edu/who-wants-to-repurpose– cheap-drugs/. Accessed Aug 21, 2024.
60. Colchicine: Drug information. UpToDate. Available at: https://medilib.ir/ uptodate/show/9293. Accessed Aug 23, 2024.
61. Arndt W, Mitnik C, Denzler KL, White S, Waters R. In vitro characterization of a nineteenth-century therapy for smallpox. PLoS One. 2012;7(3):32610. doi: 10.1371/journal.pone.0032610.
62. Richman H. The last time they politicized the treatment for an epidemic. American Thinker, May 3, 2020. Available at: https://www.americanthinker. com/blog/2020/05/the_last_time_they_politicized_the_treatment_for_ an_epidemic.html. Accessed Aug 16, 2024.
63. Madow BP. Use of antimalarial drugs as desludging agents in vascular disease processes: preliminary report. JAMA 1960;172(15):1630-1633. doi: 10.1001/JAMA.1960.03020150054010.
64. Orient JM. Treating herpes zoster with vitamin C: two case reports. J Amer PhysSurg 2006;11(1):26-27. Available at: https://www.jpands.org/vol11no1/ Orient.pdf. Accessed Aug 16, 2024.
65. Bottger F, Valles-Martf A, Cahn L, Jimenez CR. High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer. J Expt Clin Cancer Res 2021;40(1):1-44. doi: 10.1186/S13046-021-02134-Y/.
66. Crocodillin. Bionity.com. Available at: https://www.bionity.com/en/encyclopedia/Crocodillin.html#google_vignette. Accessed Aug 16, 2024.

---

Ivermectin vs Paxlavoid - by FLCCC Spring 2024

---

c19ivermectin.com

https://c19ivermectin.com/

The above images are automatically updated

CHAIRMAN OF TOKYO MEDICAL ASSOCIATION TELLS DOCTORS TO PRESCRIBE IVERMECTIN FOR COVID TREATMENT - 90 second video, Aug 26, 2021

---

10+ VitaminDWiki pages have IVERMECTIN in the title

This list is automatically updated

---

Ivermectin raises levels of vitamin D (by decreasing CYP3A4) - 6 studies

1. Interplay between Vitamin D and the Drug Metabolizing Enzyme CYP3A4 - 2014   PDF
2. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes
   • Xenobiotica, . 1998 Mar;28(3):313-21. doi: 10.1080/004982598239597
3. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects   March 2021   PDF
4. Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice? - July 2019 https://doi.org/10.1007/s00467-018-4030-3
   • 
5. CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations -2017 [|FREE PDF]
   • 
6. Vitamin D levels massively changed by CYP3A4 gene (drugs such as Ivermectin and anti-epileptics)

Note: Ivermectin treats river blindness, which is also treated by Vitamin D

---

Compare Ivermectin and vitamin D

	Ivermectin	Vitamin D
Dosing for Prevention	weekly	weekly
Availability for humans	Prescription And over-the-counter	Over-the-Counter
Form	Oral	Oral, topical, etc
COVID-19 phase Prevent, treat, long-haul	All phases	Prevent - Great Early treat - Good Late treat - poor Long-haul possibly
Allowed for COVID-19	In some places	in some places
Safe: # of doses given in 50 years	> 3 billion	> 3 billion
Able to deal with virus that has mutated	Yes	Yes
Fight more than just COVID-19	unsure	Proven 90+ health problems

Both are heavily supported by both observations and clinical trials
Not clear which is best
Note: Ivermectin raises vitamin D levels/ (see 6 studies further down this page)

---

Mikki Willis, Pierre Kory - The War on Ivermectin - 12-minute video Dec 2023

Rumble

---

The War on Ivermectin (an overview) - May 2023

Dr. Malone Substack

---

Australia had banned Invermectin use for COVID in Sept 2021, Reconsidering in Sept 2022

URL

---

Australia again ALLOWS Ivermectin to be used for any health problem - April 2023

---

Ivermectin substantially reduced COVID infection, hospitalization, death (India)- Sept 2022

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID- 19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
Cureus 14(8): e28624. DOI 10.7759/cureus.28624

Background
We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID- 19), irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajai, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID- 19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose- response effect.

Methods
This exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2 mg/kg/day for two consecutive days, every 15 days, for 150 days. Regularity definitions were as follows: regular users had 180 mg or more of ivermectin and irregular users had up to 60 mg, in total, throughout the program. Comparisons were made between non-users (subjects who did not use ivermectin), and regular and irregular users after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and the risk of dying from COVID-19. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality rates.

Results
Among 223,128 subjects from the city of Itajai, 159,560 were 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg) and 8,325 (7.3%) used regularly (more than 180 mg). The remaining 71,548 participants were not included in the analysis. COVID-19 infection rate was 49% lower for regular users (3.40%) than non-users (6.64%) (risk rate (RR): 0.51; 95% CI: 0.45-0.58; p < 0.0001), and 25% lower than irregular users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p < 0.0001). The infection rate was 32% lower for irregular users than non-users (RR: 0.68; 95% CI: 0.64-0.73; p < 0.0001). Among COVID-19 participants, regular users were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users. After PSM, the matched analysis contained 283 subjects in each group of non-users and regular users, between regular users and irregular users, and 1,542 subjects between non-users and irregular users. The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p < 0.0001), and by 29% among irregular users compared to non-users (RR: 0.781; 95% CI: 0.49-1.05; p = 0.099). Mortality rate was 92% lower in regular users than non-users (RR: 0.08; 95% CI: 0.02-0.35; p = 0.0008) and 84% lower than irregular users (RR: 0.16; 95% CI: 0.04-0.71; p = 0.016), while irregular users had a 37% lower mortality rate reduction than non-users (RR: 0.67; 95% CI: 0.40-0.99; p = 0.049). Risk of dying from COVID-19 was 86% lower among regular users than non-users (RR: 0.14; 95% CI: 0.03-0.57; p = 0.006), and 72% lower than irregular users (RR: 0.28; 95% CI: 0.07-1.18; p = 0.083), while irregular users had a 51% reduction compared to non-users (RR: 0.49; 95% CI: 0.32-0.76; p = 0.001).

Conclusion
Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.
 Download the PDF from VitaminDWiki

---

Ivermectin shows ‘antiviral effect’ against COVID (RCT- Japan) Jan 31, 2022

Ivermectin shows ‘antiviral effect’ against COVID, Japanese company says Reuters
Apparently Kowa Co. Ltd. 1000 patient Phase 3 clinical trial TrialSiteNews Jan 31
no details were given

---

Hypothesis: Ivermectin works by improving the gut microbiome - Dec 2022

Trial Site News Dec 15

• . . . . suggest heightened levels of Bifidobacterium may reduce not only inflammation levels but also TNF- α function thus contributing to “calming the cytokine storm of SARS-CoV-2 infection.”

See also

• Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19 - July 2022 https://doi.org/10.3389/fmicb.2022.952321 FREE PDF
• Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases - RCT Feb 2022 https://doi.org/10.1038/s41467-022-28658-1 FREE PDF
• Ivermectin (IVM) Possible Side Activities and Implications in Antimicrobial Resistance and Animal Welfare: The Authors’ Perspective - Jan 2022 https://doi.org/10.3390/vetsci9010024 FREE PDF

---

A series of 4 blog posts on Ivermectin - including censorship Feb-March 2022

1) Ivermectin Part 1: The Very Unusual Paper
2)
Ivermectin Part 2: A Very Unusual Business
3)Ivermectin Part 3: The People Behind the Curtain
(3.1)Part 1: An Unacknowledged Influence

• 3.2)Part 2: The Conflicts of Interest of those who discredited Ivermectin
• 3.3)Part 3: Who is Andrew Owen?

4) Ivermectin Part 4: Censorship, controversy and attacks March 23. 2022

---

Some Ivermectin Videos

• History of Ivermectin Dec 2021 10-minute video followed by discussion
  • found in soil bacteria, became top-selling drug for Veterinarians
  • Approved for humans in 1987, 4 billion doses so far,
  • single annual dose stopped river blindness, 2015 Nobel prize,
• Dr. Pierre Kory, Ivermectin, and COVID (Let’s help end the pandemic.) Feb 25. 2 hours, the same interviewer
• Covid, Ivermectin and the Crime of the Century Kory - June 1, 2021?
  • The first 5 minutes appear to be blank
• Dr. Campbell asks why Ivermectin is not being considered - video, Israel RCT June 15, 2021
  • Includes overview of recent successful Randomized Clinical Trial in Israel
    • 2.6X better reduction in viral load than placebo
• Those taking Ivermectin for COVID were 3X less likely to die (1,000 people, 18 months) – March 2022 Campbell Video March 6
• 32 Ivermectin and COVID-19 questions answered - Video May 31, 2021Mobeen Syed 22 minutes

---

Dr. Campbell pointed out the new Pfizer drug and Ivermectin work in the same way Nov 2021 - video was removed from Facebook

New Pfizer drug and ivermectin Nov 9, 2021
Alternative facts Nov 11, 2021
Facebook of his video was removed after journalists review. NOT a peer review

---

Ivermectin COVID-19 effectivity 86%, meta-analysis Aug 2021

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
 Download the PDF from VitaminDWiki
One of the authors routinely has made reviews of drugs for WHO, but WHO refused to look at Ivermectin
Sept 2021 video interview of the author,Theresa Lawrie

---

Weekly Ivermectin prevents COVID-19 - Feb 2021

Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?
 Download the PDF from VitaminDWiki

Similar to weekly vitamin D dosing, which provides far more benefits

---

Goa (1.8 million, India) to give Ivermectin every 5 days to all residents - May 11, 2021

Forbes
"...12 mg of Ivermectin for a period of five days as prophylaxis to protect against Covid-19"
"...Goa—one of India’s smallest states by population—has witnessed a recent surge in Covid-19 cases and on Tuesday it reported 3,124 new cases and 75 fatalities on Tuesday evening."

---

1 cent of Ivermectin decreased risk of COVID-19 by half (India healthcare workers) - Feb 2021

Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
 Download the PDF from VitaminDWiki
Video by Dr. john Cambell on the study - May 6, 2021

---

Ivermectin RCT in Israel: 2.6X more likely for outpatient infection to go away - preprint May 2021

Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
doi: https://doi.org/10.1101/2021.05.31.21258081

Background Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection.

Methods The double-blinded trial compared patients receiving ivermectin 0·2 mg/kg for 3 days vs. placebo in non-hospitalized COVID-19 patients. RT-PCR from a nasopharyngeal swab was obtained at recruitment and then every two days. Primary endpoint was reduction of viral-load on the 6th day (third day after termination of treatment) as reflected by Ct level>30 (non-infectious level). The primary outcome was supported by determination of viral culture viability.

Results Eighty-nine patients were eligible (47 in ivermectin and 42 in placebo arm). Their median age was 35 years. Females accounted for 21·6%, and 16·8% were asymptomatic at recruitment. Median time from symptom onset was 4 days. There were no statistical differences in these parameters between the two groups.

On day 6, 34 out of 47 (72%) patients in the ivermectin arm reached the endpoint, compared to 21/ 42 (50%) in the placebo arm (OR 2·62; 95% CI: 1·09-6·31). In a multivariable logistic-regression model, the odds of a negative test at day 6 was 2.62 time higher in the ivermectin group (95% CI: 1·06–6·45). Cultures at days 2 to 6 were positive in 3/23 (13·0%) of ivermectin samples vs. 14/29 (48·2%) in the placebo group (p=0·008).

Conclusions There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in these patients.
 Download the PDF from VitaminDWiki

---

Ivermectin reduced COVID-19 deaths in Peru by 14X - March 19, 2021

Ivermectin reduced COVID-19 deaths in Peru by 14X, after new president halted it, the death rate increased 13X – March 18, 2021

---

Top Yale Doctor/Researcher: ‘Ivermectin works,’ including for long-haul COVID - March 22, 2021

Top Yale Doctor/Researcher: ‘Ivermectin works,’ including for long-haul COVID TrialSiteNews
Prevention, treatment, and long-haul
"“When you have people that can’t breathe for five, six, eight, nine months and they tried multiple drugs and supplements with no success, and you give them ivermectin,” Dr. Santin said of long-haul patients, “and you see that they start immediately feeling better, this is not placebo. This is real.”

---

Ivermectin - Long-COVID

• IVERMECTIN IN LONG-COVID PATIENTS A RETROSPECTIVE STUDY - Feb 2021
  • Download the PDF from VitaminDWiki
• Several Facebook pages - > 1,000 Long-haul using Ivermectin at each page
• Protocol of treating long-haul with Ivermetin Mercola July 2021
  • I-RECOVER — a long-term management protocol for long-haul syndrome

---

Ivermectin reduced Vaccination Injury - Jan 2024

Campbell and Robert Clancy - 58 minute video
sSeems to decrease clotting ==> increase oxygen update
00:00:00 - Intro
00:00:01 - New medical findings on post-vaccine syndrome
00:05:59 - treatment for low oxygen saturation
00:12:22 - Patient case study, symptoms, improvement.
00:18:33 - In silico drug screening, ivermectin, spike protein
00:24:18 - Pain mechanisms, fatigue illness, autonomic disorder
00:30:36 – Iva, mechanism and treatment
00:36:52 - Repurposed drugs, virus replication, drug mechanisms
00:42:45 - Testing hypotheses, gut microbiome, immune resilience
00:48:41 - Stopped hydroxychlorin, treatment, patient experiences.

---

NOT Using Ivermectin Is Unethical And Immoral - Jan 2021

Not Using Ivermectin, One Year In, Is Unethical And Immoral TrialSiteNews
The family pushed to have Ivermectin given to the 80-year old woman in ICU
She got so much benefit that she left the ICU 48 hours later
The non-ICU portion of the hospital refused to continue the Ivermectin
The family had to sue the hospital, and the judge forced the hospital to continue the Ivermectin
She was released to a rehabilitation facility soon after

---

7X less morbidity in those African countries using Ivermectin - March 26, 2021

Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?
Preprint - doi: https://doi.org/10.1101/2021.03.26.21254377
 Download the PDF from VitaminDWiki

Background: Scientists have so far been unable to determine the reason for the low number of COVID-19 cases in Africa.

Objective: To evaluate the impact of ivermectin interventions for onchocerciasis on the morbidity, mortality, recovery, and fatality rates caused by COVID-19.

Method: A retrospective statistical analysis study of the impact of ivermectin against COVID-19 between the 31 onchocerciasis-endemic countries using the community-directed treatment with ivermectin (CDTI) and the non-endemic 22 countries in Africa. The morbidity, mortality, recovery rate, and fatality rate caused by COVID-19 were calculated from the WHO situation report in Africa. We investigated the onchocerciasis endemic 31 countries and the non-endemic 22 countries. Statistical comparisons used by the Welch test of them in the two groups were made.

Results: The morbidity and mortality were statistically significantly less in the 31 countries using CDTI. The recovery and fatality rates were not statistically significant difference. The average life expectancy was statistically significantly higher in the non-endemic countries.

Conclusions: The morbidity and mortality in the onchocerciasis endemic countries are lesser than those in the non-endemic ones. The community-directed onchocerciasis treatment with ivermectin is the most reasonable explanation for the decrease in morbidity and fatality rate in Africa. In areas where ivermectin is distributed to and used by the entire population, it leads to a significant reduction in mortality.

---

Countries using prophylactic chemotherapy with Ivermectin have far fewer COVID-19 infections - Jan 2021

A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin
Int J Antimicrob Agents. 2021 Jan;57(1):106248. doi: 10.1016/j.ijantimicag.2020.106248.
Martin D Hellwig 1, Anabela Maia 2
 Download the PDF from VitaminDWiki

COVID-19 incidence worldwide

Another chart shows similar reduction for African countries

As COVID-19 (coronavirus disease 2019) continues to rapidly spread throughout the world, the incidence varies greatly among different countries. These differences raise the question whether nations with a lower incidence share any medical commonalities that could be used not only to explain that lower incidence but also to provide guidance for potential treatments elsewhere. Such a treatment would be particularly valuable if it could be used as a prophylactic against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission, thereby effectively slowing the spread of the disease while we await the wide availability of safe and effective vaccines.
Here, we show that countries with routine mass drug administration of prophylactic chemotherapy including ivermectin have a significantly lower incidence of COVID-19. Prophylactic use of ivermectin against parasitic infections is most common in Africa and we hence show that the reported correlation is highly significant both when compared among African nations as well as in a worldwide context. We surmise that this may be connected to ivermectin's ability to inhibit SARS-CoV-2 replication, which likely leads to lower infection rates. However, other pathways must exist to explain the persistence of such an inhibitory effect after serum levels of ivermectin have declined. It is suggested that ivermectin be evaluated for potential off-label prophylactic use in certain cases to help bridge the time until a safe and effective vaccine becomes available.

---

Mercola Jan 25, 2021

Mercola

• "The data shows the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover. - FLCCC Alliance" FLCCC = Frontline COVID-19 Critical Care Alliance
• "Like hydroxychloroquine, ivermectin is an antiparasitic drug with a well-documented safety profile and “proven, highly potent, antiviral and anti-inflammatory properties.”12 It’s been on the market since 1981 and is on the World Health Organization’s list of essential medicines. It’s also inexpensive, with a treatment course costing less than $2 in countries such as India and Bangladesh"
•  FLCCC Press release Jan 7
•  FLCCC Clinical summary

---

NIH is no longer opposed to the use of Ivermectin - Jan 20, 2021

"The National Institutes of Health (NIH) has dropped its recommendation against the inexpensive antiparasitic drug ivermectin for treatment of COVID-19, and the agency now advises it can't recommend for or against its use, leaving the decision to physicians and their patients."
https://www.medscape.com/viewarticle/944440

---

Doctors Ask Arizona Gov to Facilitate COVID-19 Treatment with Ivermectin - Jan 26, 2021

Arizona chapter of American Physicians and Surgeons

---

Ivermectin protocol and experiences

https://covid19criticalcare.com/
Several Facebook pages - including Ivermectin and Long Haul

---

Use of Ivermectin did not change COVID-19 outcomes - meta-analysis Jan 29, 2021

Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and metaanalysis

 Download the PDF from VitaminDWiki

---

Covid-19: Ivermectin’s politicization is a warning sign for doctors turning to orphan treatments

British Medical Journal April 1. 2021
Doctors are not permitted to use a drug that has been successfully used over a billion times for other health problems
Interesting that US doctors are permitted to use other drugs for off-label health problems,
   but not for this particular health problem, for which tens of billions of dollars have been invested (vaccines)
     lots to be gained by promoting vaccines, but virtually no one will gain by promoting potential pre-existing solutions

---

The Drug that Cracked Covid - Ivermectin May 2021

 Download the PDF from VitaminDWiki

---

Review of Evidence: Ivermectin helps - May 2021

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

 Download the PDF from VitaminDWiki

---

Ivermectin helped in Mexico City - May 2021

• Mexico City Wide Innovative Population-Level Study Administers Ivermectin-based Home Kits with Drastic Reduction in Hospitalizations May 8, 2021

Gave Ivermectin (several pills) to those with symptoms (but not in the hospital)
"The Mexico City study team generated compelling results in that they reduced the pressures on hospital system by 52% to 76% depending on a number of factors."
COVID-19 hospitalizations

---

Bird = British Ivermectin Recomendation Development

https://bird-group.org/
Started after watching FLCCC presentation to US senate in Dec 2020
BIRD hosted the first International Ivermectin for Covid Conference in May 2021 closing video

---

Additional groups trying to get Invermetin allowed/used

FLCCC Alliance,
World Doctors Alliance,
Médicos pela Vida Brazil),
Long Covid-19 Foundation (UK),
Covid Medical Network Australia,
https://ivmmeta.com/
https://www.e-bmc.co.uk/ strongly associated with BIRD

---

Ivermectin DID NOT decrease COVID-19 severity - RCT March 2021

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 - A Randomized Clinical Trial
ivermectin, 300 μg/kg of body weight per day for 5 days
with mild disease and symptoms for 7 days or fewer (at home or hospitalized)
 Download the PDF from VitaminDWiki

---

The Scientific Misconduct Story Behind Ivermectin - Mercola Jan 2022

 Download the PDF from VitaminDWiki
Associated 9 minute Video

---

The Global Disinformation Campaign Against Ivermectin - The "Blitz"

Pierre Kory substack Nov 7, 2022

which is in The problems with healthcare in the U.S., following the disinformation playbook – Grant Dec 2017

---

- - - - Ivermectin, other than COVID

• Ivermectin used to fight Scabies TrialSite news Aug 2022
  • "“Our research shows MDA could reduce the prevalence of scabies by 90 percent after just one treatment, which could have a huge impact on children in the region."
  • Previous trial for 130,000 Fijians. was very successful, now using it for everyone
  • A mass drug administration (MDA) has been funded for all of the Solomon Islands
  • WebMD on Scabies

---

There have been 225674 visits to this page